Can big data crack the code of inflammatory bowel disease?
NCT ID NCT07166588
First seen Jun 25, 2026 · Last updated Jun 26, 2026 · Updated 1 time
Summary
This study is collecting health information from 2,000 people with Crohn's disease or ulcerative colitis across three hospitals in South Korea. Researchers aim to build computer models that can predict how each patient will respond to different treatments. No new drugs are being tested; instead, the goal is to improve personalized treatment decisions using existing data.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- What this could lead to
- If successful, this could lead to better prediction of which treatments work best for individual IBD patients, improving personalized care.
- What could go wrong
- This is an observational study, not a treatment trial. The models may not be accurate enough to change practice, and results may take years to apply.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
About 2,000 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Jan 2021
- Expected to finish
-
Dec 2028
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
Subjects with inflammatory bowel disease, including Crohn's disease and ulcerative colitis.
- Ages
-
10 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Patients aged 10 years or older who have been newly diagnosed with inflammatory bowel disease or are under follow-up monitoring. Exclusion Criteria: * Patients diagnosed with cancer or with a history of cancer treatment. * Participation may be restricted at the discretion of the medical team. * Infants and young children under the age of 10.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Crohn disease (CD) are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
The full official record for this study. This one lists no contact details, but it is the first place any would appear.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Seoul National University Hospital
Seoul, Seoul, 03080, South Korea
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Gut bacteria may hold clues to dozens of diseases
- Triple-Pronged attack on gut inflammation put to the test
- Two biologics go head to head in ulcerative colitis
- Can tissue clues predict which Crohn's patients relapse after surgery?
- New drug ATTO-1091 put to the test for safety in ulcerative colitis
- Antiparasitic drug tested as new weapon against ulcerative colitis